

PRODUCT INFORMATION



GW 3965 (hydrochloride)

Item No. 10054

CAS Registry No.: 405911-17-3
Formal Name: 3-[3-[[[2-chloro-3-(trifluoromethyl)phenyl]methyl](2,2-diphenylethyl)amino]propoxy]-benzeneacetic acid, monohydrochloride

MF: C₃₃H₃₁ClF₃NO₃ • HCl
FW: 618.5


Purity: ≥98%

UV/Vis.: λ_{max}: 204, 272 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GW 3965 (hydrochloride) is supplied as a crystalline solid. A stock solution may be made by dissolving the GW 3965 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. GW 3965 (hydrochloride) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of GW 3965 (hydrochloride) in ethanol is approximately 2 mg/ml and approximately 20 mg/ml in DMSO and DMF.

GW 3965 (hydrochloride) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GW 3965 (hydrochloride) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GW 3965 (hydrochloride) has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

The liver X receptors, LXR α and LXR β , are nuclear receptors that act as ligand-dependent transcription factors.¹ They modulate cholesterol, fatty acids, and glucose homeostasis. GW 3965 is an orally-active agonist of LXR α and LXR β , activating the human isoforms with EC₅₀ values of 190 and 30 nM, respectively.² It alters LXR-regulated gene expression in mice and rats, affecting pathways related to glucose and lipid metabolism.²⁻⁴ GW 3965 also affects inflammation and pressor responses through LXR α and LXR β .⁵⁻⁷

References

1. Gabbi, C., Warner, M., and Gustafsson, J.-Å. *Biochem. Biophys. Res. Commun.* (2013).
2. Collins, J.L., Fivush, A.M., Watson, M.A., et al. *J. Med. Chem.* **45**, 1963-1966 (2002).
3. Joseph, S.B., McKilligin, E., Pei, L., et al. *Proc. Natl. Acad. Sci. USA* **99(11)**, 7604-7609 (2002).
4. Hazra, S., Rasheed, A., Bhatwadekar, A., et al. *Diabetes* **61(12)**, 3270-3279 (2012).
5. Joseph, S.B., Castrillo, A., Lafitte, B.A., et al. *Nat. Med.* **9(2)**, 213-219 (2003).
6. Leik, C.E., Carson, N.L., Hennen, J.K., et al. *Br. J. Pharmacol.* **151(4)**, 450-456 (2007).
7. Archer, A., Stolarczyk, É., Doria, M.L., et al. *J. Lipid Res.* **54(5)**, 1300-1311 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM